Theralase Technologies Inc.
TLTFF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$51.74M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $51.74 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.02 |
| Beta | 0.59 |
| Outstanding Shares | 284,016,013 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -12.32 |
|---|---|
| PEG | -106.51 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
$126,720
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
$146,781
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Theralase Technologies Inc.
14 employees
CEO: Roger J. Dumoulin-White
Theralase Technologies Inc., founded in Toronto, Canada in 1994, is a clinical-stage pharmaceutical company focused on the development of innovative therapies and medical devices. The company's pharmaceutical division specializes in the ...